Nishadil
Signup Signin
Delhi | 25°C (windy)
Transatlantic Tremors: How US Drug Pricing Reforms Are Reshaping the Global Pharmaceutical Landscape

Transatlantic Tremors: How US Drug Pricing Reforms Are Reshaping the Global Pharmaceutical Landscape
Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs
The GLP-1 Gold Rush: Why Morgan Stanley Just Downgraded Novo Nordisk Amid Fierce Competition

The GLP-1 Gold Rush: Why Morgan Stanley Just Downgraded Novo Nordisk Amid Fierce Competition
Novo Nordisk's Groundbreaking Hemophilia A Treatment Nears FDA Review

Novo Nordisk's Groundbreaking Hemophilia A Treatment Nears FDA Review
AstraZeneca's Bold Leap: Transforming Patient Access with New Direct-to-Consumer Platform

AstraZeneca's Bold Leap: Transforming Patient Access with New Direct-to-Consumer Platform
Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule

Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule
Eli Lilly's Groundbreaking Oral Weight-Loss Pill Set to Transform India's Obesity Battle

Eli Lilly's Groundbreaking Oral Weight-Loss Pill Set to Transform India's Obesity Battle
Pfizer's Bold Gambit: Unlocking the Future of Obesity Treatment with Metsera and Oral GLP-1s

Pfizer's Bold Gambit: Unlocking the Future of Obesity Treatment with Metsera and Oral GLP-1s
Pfizer's Bold Leap: Eyeing Metsara in Blockbuster Acquisition Bid

Pfizer's Bold Leap: Eyeing Metsara in Blockbuster Acquisition Bid
Oscar Health: The Next Healthcare Moonshot Poised for Explosive Growth, Threatening a Short Squeeze

Oscar Health: The Next Healthcare Moonshot Poised for Explosive Growth, Threatening a Short Squeeze
FedEx Delivers a Market-Moving Earnings Surprise, Igniting Wall Street's Day

FedEx Delivers a Market-Moving Earnings Surprise, Igniting Wall Street's Day
Roche's Strategic Investment Ignites Excitement in the MASH Drug Development Landscape

Roche's Strategic Investment Ignites Excitement in the MASH Drug Development Landscape
Game Changer in Obesity Treatment: Novo Nordisk's Oral Wegovy Pill Achieves Remarkable 16.6% Weight Loss in Phase 3 Trial

Game Changer in Obesity Treatment: Novo Nordisk's Oral Wegovy Pill Achieves Remarkable 16.6% Weight Loss in Phase 3 Trial
FDA Steps In: Big Pharma's Weight-Loss Claims Under Scrutiny After Oprah Video

FDA Steps In: Big Pharma's Weight-Loss Claims Under Scrutiny After Oprah Video
Novo Nordisk Seeks Approval for Breakthrough Higher-Dose Wegovy, Promising Enhanced Weight Loss

Novo Nordisk Seeks Approval for Breakthrough Higher-Dose Wegovy, Promising Enhanced Weight Loss
The Final Verdict: Top Stock Picks Poised for Growth

The Final Verdict: Top Stock Picks Poised for Growth
Employers Brace for Historic Health Plan Cost Surge in 2024

Employers Brace for Historic Health Plan Cost Surge in 2024
The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance

The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance
The Weight of Success: Why Breakthrough Obesity Drugs Are a Budget Breaker

The Weight of Success: Why Breakthrough Obesity Drugs Are a Budget Breaker
Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market

Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market
The Cost-Benefit Revolution: GLP-1 Drugs Deemed Value-Packed, But Price Tags Loom Large

The Cost-Benefit Revolution: GLP-1 Drugs Deemed Value-Packed, But Price Tags Loom Large
Global Health Titans Act: FDA Tightens Grip on Safe Weight-Loss Meds as WHO Elevates Them to Essential Status

Global Health Titans Act: FDA Tightens Grip on Safe Weight-Loss Meds as WHO Elevates Them to Essential Status
Wegovy Triumphs: Novo Nordisk's Obesity Drug Significantly Cuts Heart Attack and Stroke Risk, Setting a New Benchmark in Cardiovascular Protection

Wegovy Triumphs: Novo Nordisk's Obesity Drug Significantly Cuts Heart Attack and Stroke Risk, Setting a New Benchmark in Cardiovascular Protection
Unearthing Tomorrow's Titans: Two Beaten-Down Growth Stocks Primed for Explosive Gains

Unearthing Tomorrow's Titans: Two Beaten-Down Growth Stocks Primed for Explosive Gains
Prothena's PRX012 Alzheimer's Drug Shines with 'Non-Competitive' Brain Swelling Rates, Offering New Hope

Prothena's PRX012 Alzheimer's Drug Shines with 'Non-Competitive' Brain Swelling Rates, Offering New Hope
UK Healthcare on Edge: Mounjaro Shortages Loom as Eli Lilly's Price Hike Sparks Patient Panic

UK Healthcare on Edge: Mounjaro Shortages Loom as Eli Lilly's Price Hike Sparks Patient Panic
The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?

The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?
Healthcare Titans: UnitedHealth vs. Novo Nordisk – Which Giant Dominates Your Portfolio?

Healthcare Titans: UnitedHealth vs. Novo Nordisk – Which Giant Dominates Your Portfolio?
Novo Nordisk resumes U.S. shipments of Wegovy 1.7 mg dose

Novo Nordisk resumes U.S. shipments of Wegovy 1.7 mg dose
Load more..